Structure-based mutagenesis identifies important novel determinants of the NS2B cofactor of the West Nile Virus two-component NS2B-NS3 proteinase

Inflammatory and Infectious Disease Center, Burnham Institute for Medical Research, La Jolla, CA 92037, USA.
Journal of General Virology (Impact Factor: 3.18). 04/2008; 89(Pt 3):636-41. DOI: 10.1099/vir.0.83359-0
Source: PubMed


West Nile virus (WNV) is an emerging mosquito-borne flavivirus that causes neuronal damage in the absence of treatment. In many flaviviruses, including WNV, the NS2B cofactor promotes the productive folding and the functional activity of the two-component NS3 (pro)teinase. Based on an analysis of the NS2B-NS3pro structure, we hypothesized that the G(22) residue and the negatively charged patch D(32)DD(34) of NS2B were part of an important configuration required for NS2B-NS3pro activity. Our experimental data confirmed that G(22) and D(32)DD(34) substitution for S and AAA, respectively, inactivated NS2B-NS3pro. An additional D42G mutant, which we designed as a control, had no dramatic effect on either the catalytic activity or self-proteolysis of NS2B-NS3pro. Because of the significant level of homology in flaviviral NS2B-NS3pro, our results will be useful for the development of specific allosteric inhibitors designed to interfere with the productive interactions of NS2B with NS3pro.

Download full-text


Available from: Alex Y Strongin,
  • Source
    • "Processing of the polyprotein precursor by the NS2B/NS3 protease is essential in the flavivirus life cycle (Chambers et al., 1990b), and as such, it has been one of the prime antiviral targets for WNV therapy. Typically, in vitro substrate assays are used to assess WNV NS2B/NS3 protease activity using the truncated bacterial-expressed recombinant form of the protease, NS2B 40 -G 4 SG 4 -NS3pro (Nall et al., 2004; Chappell et al., 2005, 2006, 2007, 2008a,b; Shiryaev et al., 2006, 2007a,b,c; Bera et al., 2007; Radichev et al., 2008). Nall et al. (2004) investigated the enzymatic characterization of the WNV recombinant NS2B 40 -G 4 SG 4 -NS3pro protease in vitro. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Flaviviral NS2B/NS3 heterocomplex serine proteases are a primary target for anti-flavivirus drug discovery. To gain insights into the enzymatic properties and molecular determinants of flaviviral NS2B/NS3 protease substrate specificity in host cells, we developed and applied a novel series of membrane-anchored red-shifted fluorescent protein substrates to detect West Nile virus (WNV) NS2B/NS3 endoproteolytic activity in human cells. The substrate consists of a fluorescent reporter group (DsRed) tethered to the endoplasmic reticulum membrane by a membrane-anchoring domain. Between the two domains is a specific peptide linker that corresponds to the NS2A/NS2B, NS2B/NS3, NS3/NS4A, and NS4B/NS5 protein junctions within the WNV polyprotein precursor. When the protease cleaves the peptide linker, the DsRed reporter group is released, changing its localization in the cell from membrane-bound punctate perinuclear to diffuse cytoplasmic. This change in protein location can be monitored by fluorescent microscopy, and cleavage products can be quantified by Western blotting. Our data demonstrate the robustness of our trans-cleavage fluorescence assay to capture single-cell imaging of membrane-associated WNV NS2B/NS3 endoproteolytic activity and to perform in-cell selectivity profiling of the NS2B/NS3 protease. Our study is the first to provide cellular insights into the biological and enzymatic properties of a prime target for inhibitors of WNV replication.
    Biological Chemistry 03/2010; 391(5):549-59. DOI:10.1515/BC.2010.051 · 3.27 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A grass endemic to Mexico, Sporobolus atrovirens, was identified for the first time as a desiccation-tolerant resurrection plant. Nine species of desiccation-tolerant vascular plants were found in the highland area of Mexico, including four species of ferns (Cheilanthes and Pellaea species) and three species of Selaginella. Two other grasses collected were known desiccation-tolerant species distributed from South America (Cordoba) to North America (Georgia). The ferns Ch. bonariensis, Ch. integerrima, Ch. myriophylla and P. sagittata are newly reported as desiccation-tolerant plants. The osmoprotectant trehalose which has been recorded as rare in plants was found in air-dry foliage of representative species of widely different taxa (9–291 µM g–1 dry weight). The flora of desiccation-tolerant species in Mexico is discussed in connection with its ability to accumulate trehalose.
    Australian Journal of Botany 04/2000; 48(2):153-158. DOI:10.1071/BT98062 · 1.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: West Nile Virus (WNV) has spread rapidly during the last decade across five continents causing disease and fatalities in humans and mammals. It highlights the serious threat to both our health and the economy posed by viruses crossing species, in this case from migratory birds via mosquitoes to mammals. There is no vaccine or antiviral drug for treating WNV infection. One attractive target for antiviral development is a viral trypsin-like serine protease, encoded by the N-terminal 184 amino acids of NS3, which is only active when tethered to its cofactor, NS2B. This protease, NS2B/NS3pro, cleaves the viral polyprotein to release structural and non-structural viral proteins that are essential in viral replication and assembly of new virus particles. Disruption of this protease activity is lethal for virus replication. The NS3 protein also has other enzymes within its sequence (helicase, nucleoside triphosphatase, RNA triphosphatase), all of which are tightly regulated through localisation within membranous compartments in the infected cell. This review describes the various roles of NS3, focussing on NS2B-NS3 protease and its function and regulation in WNV replication and infection. Current advances towards development of antiviral inhibitors of NS2B/NS3pro are examined along with obstacles to their development as an antiviral therapy.
    Current Medicinal Chemistry 02/2008; 15(27):2771-84. DOI:10.2174/092986708786242804 · 3.85 Impact Factor
Show more